This a very good overview, even for those who are familiar with the subject matter and on board with early treatment. I've practiced long enough that I remember when fluvoxamine was the hottest new thing since Prozac. I've seen the effort to cancel the statins to promote PCSK9 inhibitors. I think we need to rethink the generic drug concepts. In order to create competition in drug pricing, we created the patent expiration and generic drug sector. It made sense when there were few alternatives making price competition more limited. Maybe its time to discuss allowing pharma companies to retain their patent indefinitely. I know it may seem too far outside the box, but it would be vulnerable to competition from a "better mousetrap" or a lower price. That is how market should work. The current incentives are to imitate, not motivate. We need incentives to innovate, compete through value, not through influence.
Well done ! Dr.Kory never looked or sounded better. He is fearless.
Great interview!!
Excellent! youtube has banned this, however. Can you post this somewhere (Rumble, Odysee, Bitchute) where it can be downloaded so we don't lose it?
This is off the topic, but Phil, do you think there is any truth to it? US Biolabs In Ukraine Confirmed
https://www.youtube.com/watch?v=52MqHTagtQs
This a very good overview, even for those who are familiar with the subject matter and on board with early treatment. I've practiced long enough that I remember when fluvoxamine was the hottest new thing since Prozac. I've seen the effort to cancel the statins to promote PCSK9 inhibitors. I think we need to rethink the generic drug concepts. In order to create competition in drug pricing, we created the patent expiration and generic drug sector. It made sense when there were few alternatives making price competition more limited. Maybe its time to discuss allowing pharma companies to retain their patent indefinitely. I know it may seem too far outside the box, but it would be vulnerable to competition from a "better mousetrap" or a lower price. That is how market should work. The current incentives are to imitate, not motivate. We need incentives to innovate, compete through value, not through influence.